Kentucky Medical Cannabis Market Analysis: What $7.9 Million in Real Sales Says About a $126 Million Forecast

Kentucky doesn't publish a revenue dashboard, but the real number exists — it surfaced in legislative testimony instead. OMC told the state legislature on July 2 that Kentucky had shipped $4.4 million worth of product to dispensaries as of June 11 — a wholesale figure, corrected here to roughly $7.9 million in real retail terms. Full-year 2026 lands around $32–34 million. Two public forecasts put the year at $126 million and $135 million. Both run roughly four times the corrected trajectory.

Market Overview

Governor Andy Beshear signed Senate Bill 47 on March 31, 2023, legalizing medical cannabis effective January 1, 2025 — patients could register that day, but nothing existed to buy from. Cultivation began slowly through 2025 amid supply shortages and a licensing lottery criticized for letting large operators file multiple applications; regulators received 584 applications for 16 cultivation licenses. The state's Office of Medical Cannabis has also been under a formal investigation by Kentucky's Auditor of Public Accounts since April 2025, with OMC producing over a million pages of records by October — a genuine regulatory-integrity story running alongside the market one.

Kentucky's first dispensary, The Post in Beaver Dam, opened December 13, 2025 — nearly a year after patients could register. Demand was immediate: roughly 1,000 eighth-ounce packages sold in a week, some patients driving four hours to get there, at $50/eighth. The store sold out entirely by December 20 and didn't reopen until January 16, 2026. Growth since has been slow but genuine, not stalled: 17 dispensaries by early July, 23 as of August 18 (a Wilder location opened that day, ahead of the state's own directory), against 48 dispensary licenses issued in the initial round — the program can expand further as demand grows. Cultivation followed a similar initial round: 16 licenses (10 at 2,500 square feet, 4 at 10,000, 2 at 25,000), for a maximum of 115,000 square feet of canopy. Several operators appear at multiple locations under separate legal entities rather than one company name — consistent with the lottery-stacking criticism leveled at the original license round, though some of today's brand overlap also reflects licenses that have since been transferred or consolidated.

Kentucky permits raw flower but prohibits consuming it by smoking. On June 11, 2026, Beshear announced the end of a 2022 order that had granted qualifying patients a conditional pardon for buying marijuana out of state; it lapsed July 1, restoring criminal exposure without creating any new enforcement mechanism. Nine days earlier, he'd signed a separate order recognizing 15 additional diagnoses — sickle cell, ALS, Parkinson's, HIV/AIDS, fibromyalgia, and others — as falling under existing statutory language like "chronic pain," effectively expanding the program from 6 named conditions to 21. House Speaker David Osborne called it constitutionally questionable; state statute reportedly gives only the legislature or the Kentucky Center for Cannabis Research authority to add conditions. Whether it survives a challenge is unresolved — though chronic pain, broad and largely self-reported, was already one of the original six, so most of what the order adds was likely reachable anyway.

Patients and Access

Kentucky had roughly 26,000 medical cannabis cardholders by the end of June 2026. The path there wasn't a steady climb: enrollment surged from about 15,000 in October 2025 to roughly 24,000 by year-end as the first dispensaries opened, then went essentially flat for five months — 23,700 by June 2, 24,288 by June 11 — before ticking back up to 26,000 later that month. Rachel Roberts, executive director of the Kentucky Cannabis Industry Alliance, told the same legislative committee that an estimated 400,000 Kentuckians may qualify — an eligibility estimate, not an audited count. Even the recovered growth rate is nowhere near the scale 400,000 would require: nearly 500 practitioners registered statewide as of June 11, and for most of 2026, nowhere close to a full dispensary network. OMC Executive Director Cannon Armstrong told the committee that 17 dispensaries and 4 processors were operational as of July 2.

Worth putting that 400,000 figure in context: Florida, roughly five times Kentucky's population with a medical program fully operational for nine years, has reached 939,728 active patients — only about 2.35 times Kentucky's own eligibility estimate. No medical program in this dataset converts an estimate like 400,000 into real enrollment; it was always a ceiling on paper, not a realistic target.

Access is also uneven within the day, not just across the calendar. Several dispensaries in the pricing sample kept hours as short as 10 or 11 a.m. to 6 or 7 p.m. — shorter than typical retail hours elsewhere in this dataset, though not universal; at least one newer location has advertised a full 8 a.m.–8 p.m. schedule. Where it holds, it's a minor but real friction layered on top of the density problem.

The Forecast

Kentucky's population reached approximately 4.61 million in 2025, with 22.1% under 18. Netting that and an estimated 18–20 cohort yields roughly 3.37 million adults 21 and over — this series' standard normalization base, not Kentucky's actual eligibility line, which starts at 18. At the framework's 18% participation baseline and 1.0 gram/day, full capture of modeled demand comes to roughly 221 million grams — a ~$1.22 billion ceiling at $5.50/g.

Two public forecasts exist for Kentucky's 2026 market. A Factbook projection of $126 million was carried unchanged in industry coverage from August 2025 through January 2026 as a boilerplate line appended to Kentucky articles; it doesn't appear in that outlet's more substantial July 2026 reporting on the state's market. Separately, Cresco Labs' March 2025 announcement of its Kentucky cultivation license cited unnamed "industry analysts" projecting $135 million by 2026, growing to $228 million by 2028 — a forecast an actual operator underwrote capital against. Neither traces to a named, checkable methodology.

Kentucky's actual sales exist too; they just surfaced in legislative testimony rather than a dashboard. On July 2, OMC's Sam Flynn told the Interim Joint Committee on Agriculture that Kentucky had shipped more than $4.4 million worth of product to dispensaries as of June 11. Earlier in that same testimony, Flynn established wholesale pricing for the state's core products and noted retail runs double wholesale for most categories, with flower specifically excluded from that ratio — so read consistently, the $4.4 million is that same wholesale figure, not retail sell-through. Applying Flynn's 2x ratio to non-flower products and a smaller markup to flower consistent with observed retail pricing, real retail revenue through June 11 comes to approximately $7.9 million.

Weighted against the exact dates each dispensary opened, that implies roughly $2.05 million per store annualized — close to North Dakota and Hawaii, the two states in this series structurally closest to Kentucky (sparse, high-priced, medical-only). Carrying that rate through the rest of the year's dispensary openings puts full 2026 revenue at approximately $32–34 million, or about 2.6–2.8% of the $1.22 billion ceiling.

Against either figure, the gap is roughly four times.

Pricing

Menu pricing collected across a sample of Kentucky dispensaries in August 2026 clusters tightly in the $40–45 per eighth range ($11.43–$12.86/g), with one operator's advertised $35 starting price the only real outlier on the low end — and that price reportedly requires asking a budtender rather than appearing as the posted rate, an informal discount mechanic rather than a transparent one. That puts Kentucky's flower pricing at roughly 2.2x the framework's $5.50/g mature-market anchor, among the highest in this entire series — below only North Dakota's bulk pricing and Minnesota, and above New York, Utah, Virginia, and New Hampshire.

This is corroborated by a Kentucky patient's testimony at the same hearing: Ricky Hunt described paying $130 for a vape cartridge in Kentucky that cost $24 at a dispensary in Metropolis, Illinois — a 5x gap, reported by Kentucky public radio's coverage of the hearing, given after the state's out-of-state pardon had already lapsed. OMC's own cited pricing data put average costs at $40/unit for edibles and over $100 for vaporizers. The pattern held even in the sample's cheapest observed market: a dispensary in London, in southeastern Kentucky, priced no lower than the statewide range — meaning the state's poorest region, clustered in the nearby Appalachian coal counties, gets no relief on price. Harlan County's median household income is $41,693 against a $63,726 state median (ACS 2020–2024 five-year estimates, in 2024 dollars) — among the lowest in the state, though not uniquely so. It's also the region with the least physical access: none of Kentucky's 23 open dispensaries sit inside Harlan, Letcher, or the surrounding coal counties — London and Corbin, both on the region's edge, are the nearest options.

Structural Comparison

Kentucky remains below every state shown, including New Hampshire — its closest comparison in density, though New Hampshire's modeled capture of roughly 5.5% is still meaningfully above Kentucky's estimated 2.7%. Part of the gap is price, part is density, and part appears to be something more specific to Kentucky: a legally closed intrastate supply chain — no interstate commerce is permitted, per Flynn's own testimony — on top of the licensing delays every new market in this series has shown in some form.

Home Cultivation

Not permitted, for any patient, in any form. Worth noting anyway: this framework's own analysis of home cultivation puts the prohibition's real cost to the state lower than it might appear. Once the cost of dedicated grow space is counted honestly, that analysis finds home cultivation running $815–1,937 a pound — economically neutral at best against a mature market's pricing, and that's before the effort: sixteen weeks of committed space and a hundred hours of labor, against fifteen minutes at a dispensary counter. By that same analysis, fewer than 5% of consumers grow their own even where it's fully legal. Legalizing it in Kentucky wouldn't meaningfully dent commercial capture either way — the ban isn't what's standing between this market and a functioning one.

The Bottom Line

Both public forecasts run roughly four times the real trajectory, and the reasons aren't mysterious: prices still elevated even as the market expands, a dispensary network barely half-built, enrollment well short of the state's own eligibility estimate, and a legally closed supply chain with no interstate cushion. That combination — not any one factor alone — is what's suppressed capture in every sparse, high-priced medical market in this series.

What's more unusual is the gap between the 2028 figure and any visible way to close it. The number itself isn't unreasonable — $228 million is about 19% of the ceiling, roughly what South Dakota's genuinely competitive market already captures, and would take something like 100 dispensaries to reach. But all 48 licenses were awarded in a single 2024 lottery, no new round is scheduled, and the market hasn't finished opening the doors it already has. The legislature could authorize more. Given the fight already underway over how much authority Beshear can claim unilaterally — Osborne and Nemes pushing back hard, the Auditor's investigation still open — handing him room to roughly double the program's statutory ceiling looks like the harder path, not the default one. The 2028 forecast describes a real ceiling for what this market could become. It just doesn't describe one with any visible way to get there on that timeline.

This analysis applies the Dan K Reports Cannabis Market Framework. For methodology, assumptions, and the complete state-by-state comparison, see the framework documentation.